6533b837fe1ef96bd12a3451
RESEARCH PRODUCT
Randomized Comparative Trial with Ceftizoxime and Cefotaxime in Urinary Tract Infections
A. GiammancoM. Pavone-macalusoM. TripiG. Carellasubject
NephrologyAdultMalemedicine.medical_specialtyCefotaximeRandomizationAdolescentmedicine.drug_classUrologyUrinary systemCephalosporin030232 urology & nephrologyCefotaximeUrineRandom Allocation03 medical and health sciences0302 clinical medicineInternal medicineCeftizoximemedicineHumansAgedClinical Trials as Topicbusiness.industryCeftizoximeDosing regimenBacterial InfectionsDrug ToleranceGeneral MedicineMiddle AgedComparative trialSurgeryNephrology030220 oncology & carcinogenesisUrinary Tract InfectionsFemaleSafetybusinessmedicine.drugdescription
Ceftizoxime, a new, semisynthetic, beta-lactamase-resistant cephalosporin, is not metabolized in man and is excreted almost entirely as the original active compound in the urine. The efficacy and safety of ceftizoxime were assessed in 80 patients with acute and chronic urinary infections, with and without associated pathological conditions, in comparison with cefotaxime. Two dosage schedules, 1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days, were adopted according to the severity of each case and to separate randomization tables for each schedule; causal agents were all sensitive to both drugs in vitro. The overall results were excellent. Safety was excellent in almost all cases. In this trial ceftizoxime proved at least as effective and well tolerated as the reference antibiotic.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1984-08-01 | Urologia Journal |